Trimbow is a drug owned by Chiesi Farmaceutici Spa. It is protected by 6 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 23, 2034. Details of Trimbow's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10617638 | Stable Pressurized Aerosol Solution Composition Of Glycopyrronium Bromide And Formoterol Combination |
Dec, 2034
(8 years from now) | Active |
| US10159645 | Combination Therapy For Copd |
Dec, 2030
(4 years from now) | Active |
| US10806701 | Aerosol Formulation For Copd |
Dec, 2030
(4 years from now) | Active |
| US11590074 | Aerosol Formulation For Copd |
Dec, 2030
(4 years from now) | Active |
| US12357568 | Aerosol Formulation For Copd |
Dec, 2030
(4 years from now) | Active |
| US11389401 | Combination Therapy For Copd |
Dec, 2030
(4 years from now) | Active |
FDA has granted several exclusivities to Trimbow. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Trimbow, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Trimbow.
Exclusivity Information
Trimbow holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2029. Details of Trimbow's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 14, 2029 |
US patents provide insights into the exclusivity only within the United States, but
Trimbow is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Trimbow's family patents as well as insights into
ongoing legal events
on those patents.
Trimbow's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Trimbow's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 23, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Trimbow Generics:
There are no approved generic versions for Trimbow as of now.
About Trimbow
Trimbow is a drug owned by Chiesi Farmaceutici Spa. Trimbow uses Beclomethasone Dipropionate; Formoterol Fumarate; Glycopyrrolate as an active ingredient. Trimbow was launched by Chiesi in 2026.
Approval Date:
Trimbow was approved by FDA for market use on 14 May, 2026.
Active Ingredient:
Trimbow uses Beclomethasone Dipropionate; Formoterol Fumarate; Glycopyrrolate as the active ingredient. Check out other Drugs and Companies using Beclomethasone Dipropionate; Formoterol Fumarate; Glycopyrrolate ingredient
Dosage:
Trimbow is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.172MG/INH;0.0049MG/INH;0.0106MG/INH | AEROSOL, METERED | Prescription | INHALATION |
| 0.086MG/INH;0.0049MG/INH;0.0106MG/INH | AEROSOL, METERED | Prescription | INHALATION |